Interferon beta-1a (Faron Pharmaceuticals)

N/A

Report date: 2024/07/13 20:00:08

Base Information

Drug NameInterferon beta-1a (Faron Pharmaceuticals)
Drug Alias NameTraumakineMR-11A8FP-1201FP-1201-lyo
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInterferon alpha/beta receptor agonists5'-nucleotidase stimulants
TargetsInterferon alpha/beta receptor5'-nucleotidase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Organ FailureRespiratory Distress Syndrome, Adult +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[11] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFaron Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFaron Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Multiple Organ FailureRespiratory Distress Syndrome, Adult +[9] 

Other Information

ATC CodeN/A
Related LinksN/A